Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444892 · ClinicalTrials.gov registry record · Phase 2
Levodopa for Diabetic Retinopathy
A Phase 2 study of Diabetic Retinopathy, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 1
- Study location
NCT07444892 is a Phase 2 study of Diabetic Retinopathy that has completed, run by Emory University. The registered enrollment target is 230 participants, below the 1,672-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07444892, a Phase 2 study of Diabetic Retinopathy, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levodopa
Study Locations (1)
Georgia
- Atlanta VA Medical Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2025-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07444892
The ClinicalTrials.gov registry entry for NCT07444892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,672-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (86% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07444892 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT07444892 about?
NCT07444892 is a clinical study titled "Levodopa for Diabetic Retinopathy". The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.
What is the current status of trial NCT07444892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2022-04-18. Estimated completion is 2025-11-17.
What conditions does trial NCT07444892 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT07444892?
The interventions under investigation include: Placebo (DRUG), Levodopa (DRUG).
Who is sponsoring clinical trial NCT07444892?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07444892 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
A Study of PER-001 in Participants With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.